University of Wisconsin Wins $1 Million from Abbott for Health Advancement
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Updated: 2 hour ago0mins
- Surge in Donations: Amid the nation's worst blood shortage, the University of Wisconsin's 'We Give Blood' campaign achieved a 319% increase in donations, totaling 83,043, potentially saving up to 250,000 lives, highlighting the critical role of college students in social responsibility.
- Significant Student Engagement: The number of student donors rose by 168% compared to 2024, with nearly 37% of student donors participating for the first time, indicating the campaign's success in attracting younger demographics and strengthening the foundation for sustainable blood supply.
- Community Unity: This initiative not only raised health awareness within the University of Wisconsin but also inspired participation across the Big Ten Conference through friendly competition, showcasing the positive impact of sports in social good.
- Long-term Impact Outlook: The $1 million awarded by Abbott to the University of Wisconsin will be used to advance student and community health, demonstrating the potential of partnerships between corporations and educational institutions in addressing social issues and promoting future health initiatives.
ABT.N
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on ABT
Wall Street analysts forecast ABT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABT is 147.13 USD with a low forecast of 136.00 USD and a high forecast of 162.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 125.400
Low
136.00
Averages
147.13
High
162.00
Current: 125.400
Low
136.00
Averages
147.13
High
162.00
Jefferies
Jefferies
Buy
to
Hold
downgrade
$90 -> $105
2025-11-24
Reason
Jefferies
Jefferies
Price Target
$90 -> $105
2025-11-24
downgrade
Buy
to
Hold
Reason
Jefferies downgraded Exact Sciences (EXAS) to Hold from Buy with a price target of $105, up from $90, citing the pending acquisition by Abbott (ABT). The firm thinks the takeover premium represents a win for Exact Sciences and does not expect another bidder to come over the top given precedent deal multiples.
Barclays
Overweight
maintain
$159 -> $162
2025-10-17
Reason
Barclays
Price Target
$159 -> $162
2025-10-17
maintain
Overweight
Reason
Barclays raised the firm's price target on Abbott to $162 from $159 and keeps an Overweight rating on the shares. The firm recommends using the pullback following the in-line Q3 report as a buying opportunity. The shares were discounting a slightly stronger beat for Q3, the analyst tells investors in a research note. Barclays views the business weakness as temporary, and expects Abbott's portfolio to return to growth toward the high end of its historical ranges in 2026 and beyond.
Wells Fargo
Overweight
maintain
$142 -> $146
2025-10-16
Reason
Wells Fargo
Price Target
$142 -> $146
2025-10-16
maintain
Overweight
Reason
Wells Fargo raised the firm's price target on Abbott to $146 from $142 and keeps an Overweight rating on the shares. The firm notes the company reported about in-line Q3 sales and EPS on Nutrition and China Dx headwinds, offset by Medtech and EPD strength. Abbott reiterated 2025 organic sales growth and tightened its EPS guide. The company is comfortable with prior 2026 Street estimates, Wells adds.
Raymond James
Outperform
maintain
$141 -> $146
2025-10-16
Reason
Raymond James
Price Target
$141 -> $146
2025-10-16
maintain
Outperform
Reason
Raymond James raised the firm's price target on Abbott to $146 from $141 and keeps an Outperform rating on the shares. Despite organic revenue growth and EPS that hit consensus, there was an expectation for more, and while Med Devices is accelerating, the rest of the business is experiencing some lumpiness, the analyst tells investors in a research note. The firm continues to see a 7%-8% organic revenue grower capable of growing 10%+ on the bottom-line.
See All Ratings
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What are the key factors influencing ETF inflows and outflows?
How does Abbott's FreeStyle Libre 3 sensor differ from other glucose monitors?
Will Abbott's acquisition of Exact Sciences improve its position in cancer diagnostics?
How might the FDA safety alert impact Abbott's future product sales?